VA
SPRO icon

Verdad Advisers’s Spero Therapeutics SPRO Stock Holding History

Verdad Advisers’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.3K Buy
+33,455
New +$79.4K 0.09% 163

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Verdad Advisers's SPRO Position: Q1 2026 in Review

Verdad Advisers opened a new position in Spero Therapeutics (SPRO) in Q1 2026: 33,455 shares worth $78.3K. The stake represents 0.09% of the portfolio and ranks #163 among its holdings.

50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Verdad Advisers held 33,455 shares of Spero Therapeutics worth $78.3K as of Q1 2026.
  • Spero Therapeutics was a new Verdad Advisers position in Q1 2026.
  • Spero Therapeutics made up 0.09% of Verdad Advisers's portfolio in Q1 2026, its #163 holding.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.